Close Menu

NEW YORK ─ GenMark Diagnostics on Tuesday announced preliminary financial results for the second quarter of 2020, saying it anticipates 118 percent growth over the second quarter of 2019, driven primarily by sales associated with SARS-CoV-2 testing.

For the three months ended June 30, the firm expects its total revenues would be about $40.1 million compared to the $18.4 million it reported for Q2 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.